Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

974
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
974
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
T Cell Types and Functions01:24

T Cell Types and Functions

2.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

2.5K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic interphase-mediated assembly for deep cycling metal batteries.

Science advances·2021
Same author

Optimization of cardiac resynchronization therapy based on a cardiac electromechanics-perfusion computational model.

Computers in biology and medicine·2021
Same author

High-throughput deterministic pairing and coculturing of single cells in a microwell array using combined hydrodynamic and recirculation flow captures.

Biomicrofluidics·2021
Same author

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.

Frontiers of medicine·2021
Same author

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same author

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).

Signal transduction and targeted therapy·2021

Related Experiment Video

Updated: Mar 1, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K

Modified apple polysaccharide prevents colitis through modulating IL-22 and IL-22BP expression.

Yuhua Li1, Lei Fan2, Tianle Tang3

  • 1Laboratory of Oncological Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, PR China; No. 422 Hospital of PLA, Zhanjiang 524005, Guangdong, PR China.

International Journal of Biological Macromolecules
|June 6, 2017
PubMed
Summary

Modified apple polysaccharide (MAP) effectively treats dextran sodium sulfate (DSS)-induced colitis and inhibits colorectal cancer (CRC) growth in mice. MAP works by reducing Interleukin-22 (IL-22) and increasing IL-22 binding protein (IL-22BP) levels.

Keywords:
ColitisIL-22Modified apple polysaccharide (MAP)

More Related Videos

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.6K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.7K

Related Experiment Videos

Last Updated: Mar 1, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.6K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.7K

Area of Science:

  • Gastroenterology
  • Immunology
  • Oncology

Background:

  • Chronic intestinal inflammation is a precursor to colorectal cancer (CRC).
  • Apple components possess anti-inflammatory properties beneficial for colitis.
  • Modified apple polysaccharide (MAP) has shown prior efficacy in preventing colitis-associated CRC.

Purpose of the Study:

  • To evaluate the therapeutic effects of MAP on dextran sodium sulfate (DSS)-induced colitis.
  • To elucidate the underlying molecular mechanisms of MAP's action, focusing on IL-22 and IL-22BP.
  • To assess MAP's impact on colorectal cancer cell proliferation.

Main Methods:

  • Utilized a DSS-induced mouse model of colitis.
  • Employed the mouse colorectal cancer cell line MCA-38 and dendritic cell line DC2.4.
  • Applied Western blot, ELISA, BrdU staining, and co-culture systems to analyze IL-22 and IL-22BP expression.

Main Results:

  • MAP demonstrated significant protective effects against DSS-induced colitis in mice.
  • MAP treatment inhibited the proliferation of MCA-38 colorectal cancer cells.
  • MAP was observed to down-regulate IL-22 levels and up-regulate IL-22BP expression.

Conclusions:

  • MAP shows potential as a therapeutic agent for colitis.
  • MAP may serve as a preventative strategy against colorectal cancer.
  • The modulation of IL-22 and IL-22BP by MAP provides a molecular basis for its beneficial effects.